

CORRECTION

Drug-Use Evaluation Comparing Dexmedetomidine Use at 3 Health Authority Sites Relative to Manufacturer's Recommended Directions (DECODE Study): Correction

In an article comparing dexmedetomidine use in relation to recommended directions,¹ some numeric digits in Table 2 were mis-positioned during layout, leading to errors in certain of the values within the table.

The complete table is shown here. Values highlighted with bold are those that have been corrected from the original published version.

Table 2. Details of Dexmedetomidine Administration

Variable	Site; Mean ± SD*			
	All sites (n = 57)	Burnaby (n = 7)	Royal Columbian (n = 32)	Surrey Memorial (n = 18)
Bolus dose				
No. (%) of patients	24 (42)	0	17 (53)	6 (33)
Dose given (µg/kg)	1 ± 1	0	0.93 ± 0.23	1 ± 0
Infusion rate (µg/kg per hour)				
Initial rate	0.37 ± 0.17	0.40 ± 0.00	0.40 ± 0.19	0.29 ± 0.14
Minimum rate	0.25 ± 0.11	0.30 ± 0.12	0.27 ± 0.13	0.21 ± 0.02
Maximum rate	0.64 ± 0.21	0.79 ± 0.20	0.66 ± 0.20	0.61 ± 0.21
Average weighted infusion rate	0.51 ± 0.16	0.51 ± 0.13	0.54 ± 0.16	0.45 ± 0.15
Duration of therapy (h)				
Dexmedetomidine therapy	28.0 ± 17.6	19.7 ± 13.3	29.8 ± 18.1	43.1 ± 20.4
Intubation while receiving dexmedetomidine	19.4 ± 18.3	10.7 ± 11.6	21.3 ± 19.1	28.9 ± 28.6
Cost-related factors				
Total amount of drug received (µg)	1490.1 ± 212.3	896.8 ± 769.9	1494.4 ± 1136	1603.2 ± 837.9
Total cost of drug received (\$)	303.22 ± 212.26	186.85 ± 160.40	311.36 ± 236.68	334.02 ± 174.57

SD = standard deviation.

*Except where indicated otherwise.

The Journal sincerely apologizes for any inconvenience caused by these errors.

Reference

1. Boyce K, Dillon EC, Perrott J, Malyuk KL, Mabasa V, Attfield E, et al. Drug-use evaluation comparing dexmedetomidine use at 3 health authority sites relative to manufacturer's recommended directions (DECODE study). *Can J Hosp Pharm* 2014;67(5):379-86.